BioPharma Dive October 25, 2024
New manufacturing capacity recently added by Sanofi helped lift sales of the RSV antibody to 645 million euros or about $700 million, in the third quarter.
Sanofi reported a 25% boost in sales for its vaccines division during the third quarter, helped by earlier-than-anticipated orders of its flu shots as well as rising revenue from Beyfortus, its RSV antibody for infants.
Announcing earnings Friday, the French pharmaceutical company said Beyfortus sales were 645 million euros, or about $700 million. Overall, Sanofi’s vaccines unit brought in about 3.8 billion euros, driving total company sales to $13.4 billion.
The company’s performance beat Wall Street expectations, pushing its share price higher in Friday trading on French and U.S. stock exchanges.
“We reached almost...
Today's Sponsors
Today's Sponsor